振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300158 振东制药

已收盘 05-09 15:00:00

{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":3.9,"timestamp":1746774204000,"preClose":3.94,"halted":0,"volume":8553900,"delay":0,"changeRate":-0.0102,"floatShares":1002999999,"shares":1005000000,"eps":-1.3434,"marketStatus":"已收盘","change":-0.04,"latestTime":"05-09 15:00:00","open":3.95,"high":3.95,"low":3.89,"amount":33475800,"amplitude":0.0152,"askPrice":3.9,"askSize":540,"bidPrice":3.89,"bidSize":2448,"shortable":0,"etf":0,"ttmEps":-1.3434,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":5,"adr":0,"adjPreClose":3.94,"symbolType":"stock","openAndCloseTimeList":[[1746754200000,1746761400000],[1746766800000,1746774000000]],"highLimit":4.33,"lowLimit":3.55,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1005319756,"isCdr":false,"pbRate":1.08,"roa":"--","roe":"0.03%","epsLYR":-1.2977,"committee":-0.202068,"marketValue":3921000000,"turnoverRate":0.0085,"status":1,"floatMarketCap":3910000000},"requestUrl":"/m/hq/s/300158/wiki","defaultTab":"wiki","newsList":[{"id":"2531791657","title":"振东制药获得发明专利授权：“一种可掩盖苦味的女金丸制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2531791657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531791657?lang=zh_cn&edition=full","pubTime":"2025-04-30 04:04","pubTimestamp":1745957098,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示振东制药新获得一项发明专利授权，专利名为“一种可掩盖苦味的女金丸制备方法”，专利申请号为CN202311479659.5，授权日为2025年4月29日。本发明通过超微粉碎及干法压片对苦味药材进行有效掩盖，明显减轻了女金丸成药的苦味，改善了产品的口感。今年以来振东制药新获得专利授权3个，较去年同期增加了200%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025043000003537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2530813383","title":"振东制药：复方胰酶散为公司子公司产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2530813383","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530813383?lang=zh_cn&edition=full","pubTime":"2025-04-25 20:52","pubTimestamp":1745585536,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘：从公司2025年季报披露公司新增了一家：山西远景康业制药公司100%控股！复方姨酶散就是这家公司的准字药品吗？谢谢振东制药回复：尊敬的投资者您好！复方胰酶散为公司子公司山西振东安欣生物制药有限公司的产品，是公司结合批文资源与营销管线布局而“老品激活”的品种；山西远景康业制药公司为山西振东安欣生物制药有限公司的子公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500034553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0186","BK0060","300158"],"gpt_icon":0},{"id":"2530590001","title":"振东制药董事长李昆：中医药企业国际化首先要做好质量和科研","url":"https://stock-news.laohu8.com/highlight/detail?id=2530590001","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530590001?lang=zh_cn&edition=full","pubTime":"2025-04-25 18:32","pubTimestamp":1745577141,"startTime":"0","endTime":"0","summary":"4月25日，在2025企业可持续发展大会“可持续出海重塑全球商业与健康格局”分论坛上，振东制药董事长李昆发表了主题演讲《构建中药“新丝路”，从田间管理到走向国际的标准化模式》，讲述了其所在企业探索国际化发展的一些思路。李昆表示，他们做国际化的思路主要有两个，一个是质量，一个是科研，最后才考虑市场。为了保证中药产品质量，多年来，振东制药已在探索中药材如何进行追溯。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425183306a466ae0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425183306a466ae0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["561510","562390","300158","BK0186","BK0239","BK0060"],"gpt_icon":0},{"id":"2529379987","title":"振东制药：公司创新药研究围绕抗肿瘤、皮科、泌尿等管线开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2529379987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529379987?lang=zh_cn&edition=full","pubTime":"2025-04-24 20:51","pubTimestamp":1745499080,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘：2024年年报说明公司接下来要转型创新药为主攻方向，请问还是在皮科与肿瘤方向吗？公司创新药研究围绕抗肿瘤、皮科、泌尿等管线开展；公司产品生发片在京东和阿里平台上均已挂网销售，您可在相关平台上搜“达霏欣生发片”购买。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400038154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0186","BK1161","159992","300158","BK0060","BK0239","06978"],"gpt_icon":0},{"id":"2529987895","title":"振东制药：公司营销网络已实现规模化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2529987895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529987895?lang=zh_cn&edition=full","pubTime":"2025-04-24 20:51","pubTimestamp":1745499078,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘：2024年报披露，公司营收29亿，集团营收60亿，集团业务除上市公司外已经首次超过！公司以脾肾两助丸为抓手，以中药类产品集群为增长引擎，通过品牌驱动实现“群品进终端”。目前公司营销网络已实现规模化布局，已覆盖经销商626家，代理商287个，诊所、民营医院5,000家，单体药店3,000家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400038151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0186","300158"],"gpt_icon":0},{"id":"2529873499","title":"振东制药：公司暂未开展中药减肥产品方面的研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2529873499","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529873499?lang=zh_cn&edition=full","pubTime":"2025-04-24 20:51","pubTimestamp":1745499075,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药04月23日在投资者关系平台上答复投资者关心的问题。看年报公司开启2025“破局年”！公司暂未开展中药减肥产品方面的研究；公司战略并购情况请您参阅公司《2024年年度报告》第三节“管理层讨论与分析”相关内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400038147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2528854489","title":"振东制药(300158.SZ)发布2024年度业绩，归母净亏损13.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528854489","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528854489?lang=zh_cn&edition=full","pubTime":"2025-04-20 17:11","pubTimestamp":1745140309,"startTime":"0","endTime":"0","summary":"振东制药(300158.SZ)发布2024年年度报告，报告期内，公司实现营业收入2...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/13.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0186","BK0060","BK0239","300158"],"gpt_icon":0},{"id":"2528854193","title":"振东制药(300158.SZ)发布一季度业绩，归母净利润115.72万元，同比下降94.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528854193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528854193?lang=zh_cn&edition=full","pubTime":"2025-04-20 17:08","pubTimestamp":1745140115,"startTime":"0","endTime":"0","summary":"智通财经APP讯，振东制药(300158.SZ)发布2025年一季度报告，第一季度，公司实现营业收入7.55亿元，同比下降3.53%。归属于上市公司股东的净利润115.72万元，同比下降94.99%。归属于上市公司股东的扣除非经常性损益的净利润28.96万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300158"],"gpt_icon":0},{"id":"2528854396","title":"图解振东制药一季报：第一季度单季净利润同比减94.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528854396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528854396?lang=zh_cn&edition=full","pubTime":"2025-04-20 16:56","pubTimestamp":1745139364,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药2025年一季报显示，公司主营收入7.55亿元，同比下降3.53%；归母净利润115.72万元，同比下降94.99%；扣非净利润28.96万元，同比上升103.37%；负债率21.81%，投资收益341.62万元，财务费用31.15万元，毛利率49.09%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042000002600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"gpt_icon":0},{"id":"2528851186","title":"振东制药：2024年归母净利润亏损13.29亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528851186","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528851186?lang=zh_cn&edition=full","pubTime":"2025-04-20 16:33","pubTimestamp":1745137980,"startTime":"0","endTime":"0","summary":"振东制药4月20日公告，2024年实现营业收入29.71亿元，同比下降18.06%；归属于上市公司股东的净利润亏损13.29亿元，上年同期亏损4398.41万元；基本每股收益-1.2977元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-04-20/doc-inetvawy2923715.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-04-20/doc-inetvawy2923715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300158"],"gpt_icon":0},{"id":"2528851819","title":"图解振东制药年报：第四季度单季净利润同比减3074.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528851819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528851819?lang=zh_cn&edition=full","pubTime":"2025-04-20 16:32","pubTimestamp":1745137943,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药2024年年报显示，公司主营收入29.71亿元，同比下降18.06%；归母净利润-13.29亿元，同比下降2920.55%；扣非净利润-6.86亿元，同比下降491.35%；其中2024年第四季度，公司单季度主营收入7.02亿元，同比下降16.69%；单季度归母净利润-13.69亿元，同比下降3074.88%；单季度扣非净利润-6.56亿元，同比下降698.65%；负债率26.54%，投资收益4197.28万元，财务费用-121.0万元，毛利率47.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042000002420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"gpt_icon":0},{"id":"2512457753","title":"振东制药（300158）2月19日主力资金净卖出1017.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512457753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512457753?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:24","pubTimestamp":1740014673,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月19日收盘，振东制药报收于3.94元，下跌0.25%，换手率1.84%，成交量18.41万手，成交额7254.47万元。近5日资金流向一览见下表：振东制药融资融券信息显示，融资方面，当日融资买入527.61万元，融资偿还462.72万元，融资净买入64.89万元。振东制药主营业务：肿瘤、毛发、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000008022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"gpt_icon":0},{"id":"2512517719","title":"振东制药最新公告：中药1.1类新药星蒌承气颗粒获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512517719","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512517719?lang=zh_cn&edition=full","pubTime":"2025-02-19 18:41","pubTimestamp":1739961673,"startTime":"0","endTime":"0","summary":"振东制药公告称，公司研发的星蒌承气颗粒近日获得国家药品监督管理局出具的《药物临床试验批准通知书》。该药品为中药1.1类新药，用于治疗急性缺血性脑卒中。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900033336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1583","BK0239","BK0186","BK1576","03347","BK0060","300158"],"gpt_icon":0},{"id":"2512773381","title":"振东制药(300158.SZ)：中药1.1类新药星蒌承气颗粒获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512773381","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512773381?lang=zh_cn&edition=full","pubTime":"2025-02-19 18:39","pubTimestamp":1739961561,"startTime":"0","endTime":"0","summary":"智通财经APP讯，振东制药(300158.SZ)公告，公司研发的星蒌承气颗粒近日获得国家药品监督管理局出具的《药物临床试验批准通知书》。经审查，星蒌承气颗粒临床试验申请符合药品注册的有关要求，在进一步完善临床试验方案的基础上，同意开展用于急性缺血性脑卒中的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK0239","300158","BK0060","BK1583","03347","BK0186","BK1576"],"gpt_icon":0},{"id":"2512988177","title":"【振东制药：中药1.1类新药星蒌承气颗粒获临床试验批准】振东制药公告，公司研发的星蒌承气颗粒近日获得国家药品监督管理局出具的《药物临床试验批准通知书》。该药物功能主治为化痰清热，通腑泻下，用于缺血性脑卒中急性期痰热腑实证，症见半身不遂、偏身麻木、言语不利、头晕目眩，且兼有腹胀、便秘便干、痰多而黏、舌质红、舌苔黄腻。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512988177","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512988177?lang=zh_cn&edition=full","pubTime":"2025-02-19 18:39","pubTimestamp":1739961540,"startTime":"0","endTime":"0","summary":"振东制药公告，公司研发的星蒌承气颗粒近日获得国家药品监督管理局出具的《药物临床试验批准通知书》。该药物功能主治为化痰清热，通腑泻下，用于缺血性脑卒中急性期痰热腑实证，症见半身不遂、偏身麻木、言语不利、头晕目眩，且兼有腹胀、便秘便干、痰多而黏、舌质红、舌苔黄腻。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/19183948263341.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK0060","300158","03347","BK1576","BK0186","BK1583","BK0239"],"gpt_icon":0},{"id":"2509773066","title":"振东制药（300158）2月6日主力资金净卖出1291.24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509773066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509773066?lang=zh_cn&edition=full","pubTime":"2025-02-07 09:28","pubTimestamp":1738891704,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月6日收盘，振东制药报收于3.9元，上涨0.0%，换手率2.39%，成交量23.96万手，成交额9296.68万元。近5日资金流向一览见下表：振东制药融资融券信息显示，融资方面，当日融资买入535.45万元，融资偿还479.61万元，融资净买入55.84万元。振东制药主营业务：肿瘤、毛发、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020700006930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2505622796","title":"振东制药：2024年度业绩预告为财务部门初步测算结果将在年报中详细披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2505622796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505622796?lang=zh_cn&edition=full","pubTime":"2025-01-21 21:00","pubTimestamp":1737464431,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药01月21日在投资者关系平台上答复投资者关心的问题。对朗迪公司的预付款及应收款具体多少振东制药董秘：尊敬的投资者您好！公司于2025年1月17日披露的《2024年度业绩预告》是公司财务部门初步测算的结果，具体财务数据公司将在2024年年度报告中详细披露，有关情况请以公司后续披露的定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012100038439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300158","BK0186","BK0060"],"gpt_icon":0},{"id":"2505216557","title":"振东制药发布业绩预亏公告！非经常损益或已挤出，利润有望迎反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2505216557","media":"大消费之家","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505216557?lang=zh_cn&edition=full","pubTime":"2025-01-21 12:13","pubTimestamp":1737432780,"startTime":"0","endTime":"0","summary":"天眼查信息显示，李安平当前通过振东集团持有振东制药30.06%的股份，仍为公司的实控人。非经常损益或已挤出，利润有望反弹从振东制药各季度财报数据来看，2024年上半年公司实现营业收入15.07亿元，同比下降22.05%；前三季度实现营业收入22.69亿元，同比下降18.48%。看似喜人，但进一步研究会发现，振东制药净利润大幅增长的原因并非来自主营业务的提升，因为扣非净利润一直为负数。但这种非经常性损益带来的利润增长不具有可持续性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-21/doc-ineftfhz8658093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0186","BK0239","300158","BK0060"],"gpt_icon":0},{"id":"2504115288","title":"振东制药（300158）股东山西振东健康产业集团有限公司质押4060万股，占总股本4.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504115288","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504115288?lang=zh_cn&edition=full","pubTime":"2025-01-20 21:42","pubTimestamp":1737380572,"startTime":"0","endTime":"0","summary":"证券之星消息，振东制药1月20日公开信息显示，股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押4060.0万股，占总股本4.04%。质押详情见下表：截止本公告日，股东山西振东健康产业集团有限公司已累计质押股份2.26亿股，占其持股总数的74.75%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000034227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"gpt_icon":0},{"id":"2504442622","title":"多只业绩预亏股开盘大跌，最高跌超17%！十大预亏股，最高亏损可达95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504442622","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504442622?lang=zh_cn&edition=full","pubTime":"2025-01-20 11:42","pubTimestamp":1737344520,"startTime":"0","endTime":"0","summary":"　　1月20日，多只业绩预亏股开盘大跌，*ST中程（维权）跌17.47%，振东制药跌15.72%，天微电子跌12.46%，东晶电子、海南椰岛、铖昌科技等跌停。振东制药称，预计非经常性损益对公司归属于上市公司股东的净利润的影响约为-5.6亿元至-5.8亿元。天微电子称业绩预亏的原因较多，一是2024年订单减少，导致2024年度收入下滑；二是收入调整以及减值准备的影响；三是本期收到的政府补助大幅度减少、同时研发费用大幅度增加。投资者据此操作，风险自担。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-01-20/doc-inefqwac9688093.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-20/doc-inefqwac9688093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0020","601005","BK0188","BK0005","BK0224","BK0113","BK0116","BK0044","BK0112","600340","BK0273","BK0054","BK0196","BK0077","001270","002693","600881","BK0059","BK0006","BK0028","BK0071","BK0143","BK0214","BK0040","BK0215","BK0187","BK0057","BK0238","300208","BK0139","BK0199","600500","600238","601106","300158","002199","BK0251","BK0004","600376","BK0060","601588","BK0178","600745","BK0088","BK0235","688303","BK0186","600438","LU1655091616.SGD","BK0010"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746947115132,"stockEarnings":[{"period":"1week","weight":0.0236},{"period":"1month","weight":0.0156},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.2486},{"period":"1year","weight":-0.2543},{"period":"ytd","weight":-0.0972}],"compareEarnings":[{"period":"1week","weight":0.0192},{"period":"1month","weight":0.0487},{"period":"3month","weight":0.0116},{"period":"6month","weight":-0.0319},{"period":"1year","weight":0.0595},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48584人(较上一季度减少3.92%)","perCapita":"20635股","listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","registeredCapital":"100531万元","survey":"　　山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售，以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。","listedPrice":38.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}